$DCOY

Decoy Therapeutics (NASDAQ:DCOY) plans to file a drug application for its pan-coronavirus candidate in 2H 2027. The company reported $8.1M in cash, including $2.5M from the Gates Foundation, and 2.39M shares outstanding as of September 30, 2026. Its lead program targets high-risk patients and will undergo Phase 1 and 2a trials. The company is also exploring a pan-filovirus program and seeking strategic collaborations.

Decoy Therapeutics (NASDAQ: DCOY) reported preclinical data showing that its DCOY-CoV program, designed to protect against endemic coronaviruses, can be administered once-weekly via intranasal dosing. The data, presented at the Boulder Peptide Symposium, showed sustained therapeutic drug levels in respiratory tissues for up to seven days. The company aims to address the high unmet need in over 20 million high-risk patients, including immunocompromised individuals and those with COPD.

Decoy Therapeutics Inc. (DCOY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules Houston, TX., September 22, 2026 – Decoy Therapeutics, Inc. (NASDAQ: DCOY) (“the Company” or “Decoy”), a biotechnology comp

Worthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.

Decoy Therapeutics (NASDAQ: DCOY) stock surged 87.89% to $4.81 on news of FDA Animal Rule pathway for its D-MAVs. The biotech company announced a pan-filovirus program targeting Ebola and Marburg viruses, aiming for expedited regulatory approval and non-dilutive government grants. The stock was Nasdaq's top gainer with high trading volume.

Decoy Therapeutics (DCOY) announced a warrant inducement transaction with an institutional investor, exercising 1,184,434 warrants at $3.25 per share, raising $3.85M. The company will use proceeds for working capital. New warrants for 2,368,868 shares were issued, exercisable after stockholder approval. The transaction is expected to close on September 23, 2026.

Decoy Therapeutics (DCOY) is exploring a pan-filovirus program via the FDA Animal Rule pathway, targeting Ebola and Marburg viruses. The company's D-MAVs showed potent in vitro activity, with a low-micromolar IC50 against Ebola Zaire. Decoy is pursuing non-dilutive funding and aims for Priority Review Voucher eligibility, which could provide significant capital.

Decoy Therapeutics Inc. (DCOY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 14, 2026, Decoy Therapeutics Inc. (the “Company”) convened a Special Meeting of Stockholders (the “Special Meeting”). As of July 20, 2026, the record date for the Special Meeting, there were 590,185 shar

Opus Genetics (IRD) rose 27% after positive clinical trial data. Quantum (QNTM) gained 10% with FDA Phase 2 trial clearance. Pulse Biosciences (PLSE) surged 15% without specific news. Decoy Therapeutics (DCOY) and ONWARD Medical (ONWD.BR) also traded higher on updates.

Decoy Therapeutics (NASDAQ:DCOY) said its IP portfolio grew to seven patent families and 19 pending applications in seven jurisdictions, including one granted U.S. patent. The filings cover antiviral peptide conjugates, peptide synthesis and linker methods, and compounds targeting conserved viral fusion protein features, including measles and Nipah. The company also filed a June 2026 application tied to its IMPACT platform.